Recruiting

Observational Study

Sponsor:

George Zogopoulos

Code:

NCT04104230

Conditions

Pancreas Cancer

Pancreatic Cancer

Pancreas Neoplasm

Pancreas Cyst

Pancreatic Precancerous Condition

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related cancer or a related pre-cancerous condition, and their families.

Conditions

Pancreas Cancer

Pancreatic Cancer

Pancreas Neoplasm

Pancreas Cyst

Pancreatic Precancerous Condition

Study ID

NCT04104230

Start date

Mar 12, 2012

Status verified date

Apr, 2024

Completion date

Jan, 2025

Anticipated

Primary completion date

Jan, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Individual diagnosed with pancreatic cancer.
  • Individual diagnosed with a related cancer (bile duct cancer, ampullary cancer, duodenal cancer, gallbladder cancer).
  • Individual diagnosed with pancreatic neoplasm or pancreatic cyst.
  • High-risk individuals with Familial Pancreatic Cancer (3 or more relatives affected with adenocarcinoma).
  • High-risk individuals with 2 first-degree relatives affected with young-onset pancreatic adenocarcinoma (≤ 50 years old).
  • High-risk individuals with one of the following Hereditary Cancer Syndromes: Peutz-Jeghers Syndrome (STK11 gene mutation), Familial Atypical Multiple Mole Melanoma Syndrome (CDKN2A gene mutation), or Hereditary Pancreatitis (PRSS1 gene mutation) with clinical manifestations.
  • High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITH a family history of cancer.

Exclusion Criteria:

  • High-risk individuals with one of the following Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2 or PALB2 gene mutation), Lynch Syndrome (MLH1, MSH2, MSH6, PMS2 or EPCAM gene mutation), or Hereditary Breast Cancer (ATM gene mutation), WITHOUT a family history of cancer.

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Individuals Affected With Pancreatic Cancer

Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.

Individuals Affected with Related Cancer

Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.

Individuals Affected With Pancreatic Neoplasm

Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.

High-Risk Individuals

Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.

Healthy Controls

Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.

Primary outcome measure

  • Knowledge and Tissue Bank [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Adeline Cuggia, MSc

514-934-1934cancer.pancreas@mcgill.ca

Locations

McGill University Health Centre

Recruiting

Montréal, Quebec, Canada, H4A 3J1

Contacts

Adeline Cuggia, MSc

514-934-1934cancer.pancreas@mcgill.ca

Principal Investigator:

George Zogopoulos, MD, PhD

More Information

Sponsor

George Zogopoulos

Last update posted

Apr 17, 2024

Last verified

Apr, 2024

Keywords

  • Cancer Genetics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by George Zogopoulos on 2024-04-17.